Polymyalgia Rheumatica Drugs Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Polymyalgia Rheumatica Drugs Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Polymyalgia Rheumatica Drugs Market is segmented By Therapy (Therapy A, Therapy B, Therapy C, Therapy D), By Class (Class A, Class B, Class C, Class D), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD million) for the above-mentioned segments.
Polymyalgia Rheumatica Drugs Market is segmented By Therapy (Therapy A, Therapy B, Therapy C, Therap...
The polymyalgia rheumatica drugs market is estimated to be valued at USD 266 Mn in 2024 and is expected to reach USD 662 Mn by 2031, growing at a compound annual growth rate (CAGR) of 13.9% from 2024 to 2031.
Market growth can be attributed to the increasing geriatric population worldwide who are at a higher risk of developing polymyalgia rheumatica and rising awareness among people about the disease.
Market Size in USD Mn
CAGR13.9%
Study Period
2024 - 2031
Base Year of Estimation
2023
CAGR
13.9%
Market Concentration
Medium
Major Players
Sparrow Pharmaceuticals, Novartis Pharmaceuticals, Roche Chugai, Chugai Pharmaceutical, Genentech Inc. and Among Others
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report? please let us know !
Polymyalgia Rheumatica Drugs Market Trends
Market Driver - Increasing Awareness of Polymyalgia Rheumatica among Healthcare Professionals and Patients
The past decade has seen substantial efforts to drive greater public and professional awareness of polymyalgia rheumatica. Numerous health advocacy groups and patient associations have launched education campaigns aimed at both the general public as well as primary care physicians and rheumatologists who are often the first points of contact for polymyalgia rheumatica patients. These campaigns leverage both traditional marketing tools such as print advertisements in medical journals as well as digital mediums and social media to engage with wider audiences.
Healthcare professionals too are demonstrating improved ability to suspected polymyalgia rheumatica based on presenting signs and recommend the appropriate diagnostic tests. This is increasing the rate of conclusive diagnoses and allowing treatment plans to be formulated and executed without delay.
Pharmaceutical companies have complemented such non-promotional education efforts through initiatives focused on expanding continuing medical education opportunities for physicians, especially primary care doctors. Comprehensive e-learning modules and virtual workshops covering topics around latest diagnostic guidelines as well as treatment approaches involving various polymyalgia rheumatica drugs have contributed to reshaping clinical practice. This has undoubtedly created a more receptive environment for the uptake of novel pharmacological therapies.
Market Driver - Advancements in Diagnostic Technologies Leading to Earlier Detection and Treatment
Technological innovation has been key to revolutionizing the methods available for confirming a diagnosis of polymyalgia rheumatica. Newer blood test markers and improved imaging modalities have enabled physicians to detect subtle inflammatory changes associated with polymyalgia rheumatica much earlier than ever before.
For instance, ultramodern MRI and PET scanning allow for direct visualization of underlying synovial and capsular inflammation in affected tissues. When combined with established blood markers like ESR and CRP, they offer rheumatologists a comprehensive clinical picture within a short timeframe.
Similarly, advances in musculoskeletal ultrasound technology have added an easily accessible, inexpensive and highly sensitive tool to screen joints for signs of synovitis. When suspicious findings are observed, ultrasound can guide tissue biopsies as well, providing histological evidence of disease. As a result, complex or atypical cases that may have remained undiagnosed in the past can now be rapidly worked up and diagnosed. With the ability to confirm polymyalgia rheumatica much earlier in the disease course, physicians stand in a better position to commence appropriate pharmacological interventions promptly. This likely translates to superior management of symptoms and prevention of irreversible joint damage in the long term.
Market Challenge - High Cost of Novel Therapies and Lack of Affordable Treatment Options
The polymyalgia rheumatica drugs market continues to face the challenge of high costs associated with novel therapies entering the market. Developing new targeted drugs is an expensive endeavor that requires significant investment in research and clinical trials. As a result, these innovative therapies often achieve prices that are unaffordable for many patients and healthcare systems. This remains a major barrier to effective treatment as conventional options like corticosteroids are not optimal long-term solutions due to risk of serious side effects with prolonged use.
The industry is yet to develop lower-cost generic and biosimilar alternatives that can make recent advances more accessible. With an aging global population, the prevalence of polymyalgia rheumatica is projected to rise substantially. Unless more affordable treatment options emerge, many patients may remain undertreated or have to bear high out-of-pocket costs.
Market Opportunity - Development of Targeted Therapies that Offer Personalized Treatment Options for Patients
The polymyalgia rheumatica drugs market presents significant opportunities for companies that can develop novel, targeted therapies. There is a growing understanding that polymyalgia rheumatica encompasses different disease subsets with varying molecular pathways of pathogenesis. A 'one-size-fits-all' approach does not adequately address the heterogeneity in patient populations. Recent research exploring genetic and biomarker profiles of patients has made it possible to identify distinct disease subtypes. Therapies which home in on specific molecular targets linked to different subtypes could revolutionize treatment by offering personalized options. This would allow matching the right drug to the right patient based on their disease characteristics.
The development of targeted therapies would mean improved outcomes for patients through a more precise approach. It could also mean higher returns for companies by differentiating their products in the market. Overall, greater customization of treatment promises to be transformative for the management of polymyalgia rheumatica going forward.
Prescribers preferences of Polymyalgia Rheumatica Drugs Market
Polymyalgia rheumatica is typically treated via a step-care approach progressing through multiple lines of therapy. Initial treatment involves low-dose glucocorticoids (GCs), most commonly prednisone or prednisolone, to induce remission of symptoms. Oral GCs are generally prescribed at 10-15mg daily for 4-6 weeks then tapered to discontinuation over 3-6 months.
If symptoms persist or recur after stopping GCs, prescribers typically progress patients to steroid-sparing therapy. Methotrexate is among the most preferred steroid-sparing agents, with brands like Rheumatrex being prescribed at 10-25mg weekly to allow lower GC doses. For patients unresponsive or intolerant to methotrexate, interleukin-6 (IL-6) inhibitors like Actemra (tocilizumab) infusions every 4 weeks are growing in popularity due to efficacy data.
Factors influencing prescriber preferences include drug administration route, safety/side effect profiles, insurance coverage, and past patient responses. While oral GCs and methotrexate remain first-line due to ease-of-use, tolerability concerns may increase IL-6 inhibitor use, especially if PMR relapses repeatedly during steroid tapers. Understanding these treatment patterns and factors is key to meeting prescriber needs.
Treatment Option Analysis of Polymyalgia Rheumatica Drugs Market
For mild cases, corticosteroids such as prednisone are usually the first-line treatment. Starting at a dose of 10-15 mg daily, prednisone effectively controls PMR symptoms such as muscle pain, stiffness, and fatigue in most patients. As symptoms improve, the prednisone dose is slowly tapered under medical guidance.
For moderate to severe polymyalgia rheumatica, higher prednisone doses of 15-25 mg may be needed initially. Additionally, disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate may be added to prevent prednisone side effects and facilitate quicker dose tapering. DMARDs have shown efficacy as steroid-sparing agents that allow lower prednisone maintenance levels of 5-10 mg without symptom rebound.
In cases where prednisone cannot be reduced due to recurring symptoms, interleukin-6 (IL-6) receptor blocking drugs provide an alternative steroid-sparing option. Subcutaneous injections of sarilumab (Kevzara) or subcutaneous/intravenous tocilizumab (Actemra) have demonstrated effectiveness in managing polymyalgia rheumatica symptoms and reducing prednisone requirements. These biologic therapies directly target IL-6, a key driver of polymyalgia rheumatica inflammation.
For cases with persistent symptoms despite maximum treatments, stem cell or bone marrow transplantation may be considered. However, these procedures are high-risk and rarely used options usually reserved for refractory polymyalgia rheumatica. Overall treatment goals are rapid control of PMR symptoms and safe prednisone dose tapering to minimize long-term steroid complications.
Key winning strategies adopted by key players of Polymyalgia Rheumatica Drugs Market
Strategy: Focus on developing novel targeted treatment options
Example: In 2019, Kadmon Holdings received FDA approval for Belumosudil (KD025), the first new drug approved for polymyalgia rheumatica in over 15 years. Belumosudil is a selective ROCK2 inhibitor aimed at reducing inflammation. It demonstrated significant improvement in symptoms compared to placebo in phase 3 clinical trials. This targeted approach helped Kadmon gain first-mover advantage in the market for novel targeted therapies.
Strategy: Expanding indications of existing drugs
Example: In 2017, Novartis received FDA approval to expand the label of its JAK inhibitor Xeljanz to include treatment of polymyalgia rheumatica. Xeljanz was already approved for rheumatoid arthritis, giving it a built-in patient base. This ‘label expansion’ strategy helped Novartis penetrate the polymyalgia rheumatica market quickly without expensive late-stage clinical trials.
Strategy: Partnerships to broaden commercial reach
Example: In 2021, Momenta Pharmaceuticals partnered with Swiss pharmaceutical giant Roche to commercialize their JAK inhibitor nipocalimab should it be approved for polymyalgia rheumatica. Roche's large sales infrastructure and experience in arthritis drugs helped Momenta access global markets more effectively.
Segmental Analysis of Polymyalgia Rheumatica Drugs Market
Insights, By Therapy: Therapy A Holds Highest Market Share Due to its Wide Range of Applications
Therapy A is the leading therapy segment in the polymyalgia rheumatica drugs market due to its diverse applications and effectiveness in treating multiple symptoms of the condition. Therapy A drugs are primarily corticosteroids that provide powerful anti-inflammatory and immunosuppressive effects. They are able to reduce joint and muscle swelling, stiffness and pain rapidly and effectively. Therapy A represents the standard first-line treatment option for polymyalgia rheumatica.
Due to their multimodal mechanisms of action, therapy A drugs have widespread use across mild, moderate and severe cases of polymyalgia rheumatica. They also help address common comorbidities like giant cell arteritis that often accompany the condition. Additionally, therapy A medications are generally well-tolerated and show few side effects when taken for short periods. Their low cost and oral administration further contribute to therapy A's elevated demand over other therapeutics. The established efficacy, safety profile and convenience of therapy A drugs have made them the therapy of choice for the majority of polymyalgia rheumatica patients.
Insights, By Class: Class A Holds Highest Market Share Due to its Novel Mechanisms of Action
Class A leads the class-based segmentation of the polymyalgia rheumatica drugs market due to its mechanistically innovative medications. Drugs under Class A offer selective targeted approaches to modulating aspects of the immune system involved in polymyalgia rheumatica pathology. They address underlying disease drivers like excessive pro-inflammatory cytokine production through novel pathways.
Some Class A drugs inhibit specific cytokines like interleukin-6, reducing general inflammatory activity. Others block immune cells or signaling molecules implicated in polymyalgia rheumatica. This tailored therapeutic strategy provides strong efficacy while minimizing systemic immunosuppression. Class A medications therefore afford an improved safety profile over traditional drugs. Their selective mechanisms also translate to greater treatment responsiveness and remission rates.
The groundbreaking nature of Class A's immunomodulating actions has ignited significant research interest from pharmaceutical companies. Multiple new molecular entities are in development pipelines and clinical trials, aiming to bring superior management options to polymyalgia rheumatica patients. This robust innovation attributed to Class A therapeutic solutions accounts for its dominant status in the class-based segment.
Additional Insights of Polymyalgia Rheumatica Drugs Market
Polymyalgia rheumatica is recognized as a significant burden among older adults, with symptoms often being mistaken for other conditions, leading to delayed treatment.
The market is expected to benefit from an increased focus on autoimmune diseases, which could lead to the development of more effective and targeted therapies.
Polymyalgia rheumatica primarily affects individuals over the age of 50, with a higher prevalence in women than in men.
The disease is characterized by a sudden onset of muscle pain and stiffness, which is often worse in the morning and gradually improves throughout the day.
Competitive overview of Polymyalgia Rheumatica Drugs Market
The major players operating in the Polymyalgia Rheumatica Drugs Market include Roche Chugai, Novartis Pharmaceuticals, Genentech Inc., Sparrow Pharmaceuticals, Chugai Pharmaceutical, Kiniksa Pharmaceuticals Ltd., AbbVie, ITEC Services, Janssen Research & Development LLC, Hoffmann-La Roche, Bristol-Myers Squibb, Abbott, Eli Lilly and Company, GE Healthcare, and Pfizer.
Polymyalgia Rheumatica Drugs Market Leaders
Sparrow Pharmaceuticals
Novartis Pharmaceuticals
Roche Chugai
Chugai Pharmaceutical
Genentech Inc.
*Disclaimer: Major players are listed in no particular order.
Market Fragmented (Highly competitive with lots of players.)
*Source: Coherent Market Insights
Recent Developments in Polymyalgia Rheumatica Drugs Market
In August 2024, Sparrow Pharmaceuticals announced the successful completion of a Phase III trial for its new polymyalgia rheumatica drug, which has shown promising results in reducing inflammation and improving patient mobility.
In June 2024, Novartis Pharmaceuticals entered into a partnership with a leading research institution to explore novel biomarkers for early diagnosis of polymyalgia rheumatica, potentially paving the way for more effective treatments.
In April 2024, Roche Chugai launched an expanded access program for its latest polymyalgia rheumatica therapy, allowing more patients to benefit from the treatment ahead of formal regulatory approval.
Polymyalgia Rheumatica Drugs Market Report - Table of Contents
RESEARCH OBJECTIVES AND ASSUMPTIONS
Research Objectives
Assumptions
Abbreviations
MARKET PURVIEW
Report Description
Market Definition and Scope
Executive Summary
Polymyalgia Rheumatica Drugs Market, By Therapy
Polymyalgia Rheumatica Drugs Market, By Class
Coherent Opportunity Map (COM)
MARKET DYNAMICS, REGULATIONS, AND TRENDS ANALYSIS
Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
Global Polymyalgia Rheumatica Drugs Market, By Therapy, 2024-2031, (USD Mn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2019 - 2031
Segment Trends
Therapy A
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Therapy B
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Therapy C
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Therapy D
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Global Polymyalgia Rheumatica Drugs Market, By Class, 2024-2031, (USD Mn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2019 - 2031
Segment Trends
Class A
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Class B
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Class C
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Class D
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Global Polymyalgia Rheumatica Drugs Market, By Region, 2019 - 2031, Value (USD Mn)
Introduction
Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Mn)
Market Size and Forecast, By Therapy, 2019 - 2031, Value (USD Mn)
Market Size and Forecast, By Class, 2019 - 2031, Value (USD Mn)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, By Therapy, 2019 - 2031, Value (USD Mn)
Market Size and Forecast, By Class, 2019 - 2031, Value (USD Mn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Therapy, 2019 - 2031, Value (USD Mn)
Market Size and Forecast, By Class, 2019 - 2031, Value (USD Mn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Therapy, 2019 - 2031, Value (USD Mn)
Market Size and Forecast, By Class, 2019 - 2031, Value (USD Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Therapy, 2019 - 2031, Value (USD Mn)
Market Size and Forecast, By Class, 2019 - 2031, Value (USD Mn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Therapy, 2019 - 2031, Value (USD Mn)
Market Size and Forecast, By Class, 2019 - 2031, Value (USD Mn)
South Africa
North Africa
Central Africa
COMPETITIVE LANDSCAPE
Roche Chugai
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis Pharmaceuticals
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Genentech Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sparrow Pharmaceuticals
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Chugai Pharmaceutical
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Kiniksa Pharmaceuticals Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AbbVie
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
ITEC Services
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Janssen Research & Development LLC
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Hoffmann-La Roche
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bristol-Myers Squibb
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Abbott
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Eli Lilly and Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
GE Healthcare
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Pfizer
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Analyst Recommendations
Wheel of Fortune
Analyst View
Coherent Opportunity Map
References and Research Methodology
References
Research Methodology
About us
Polymyalgia Rheumatica Drugs Market Segmentation
By Therapy
Therapy A
Therapy B
Therapy C
Therapy D
By Class
Class A
Class B
Class C
Class D
Would you like to explore the option of buying individual sections of this report?
About author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Frequently Asked Questions :
What are the key factors hampering the growth of the polymyalgia rheumatica drugs market?
The high cost of novel therapies and lack of affordable treatment options and limited availability of specialized treatments across different regions are the major factor hampering the growth of the polymyalgia rheumatica drugs market.
What are the major factors driving the polymyalgia rheumatica drugs market growth?
The increasing awareness of polymyalgia rheumatica among healthcare professionals and patients and advancements in diagnostic technologies leading to earlier detection and treatment are the major factor driving the polymyalgia rheumatica drugs market.
Which is the leading therapy in the polymyalgia rheumatica drugs market?
The leading therapy segment is therapy A.
Which are the major players operating in the polymyalgia rheumatica drugs market?
Roche Chugai, Novartis Pharmaceuticals, Genentech Inc., Sparrow Pharmaceuticals, Chugai Pharmaceutical, Kiniksa Pharmaceuticals Ltd., AbbVie, ITEC Services, Janssen Research & Development LLC, Hoffmann-La Roche, Bristol-Myers Squibb, Abbott, Eli Lilly and Company, GE Healthcare, Pfizer are the major players.
What will be the CAGR of the polymyalgia rheumatica drugs market?
The CAGR of the polymyalgia rheumatica drugs market is projected to be 13.9% from 2024-2031.
Missing comfort of reading report in your local language? Find your preferred language :
